// App-Quantinova.ai

O-12 : KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Researchers

Presenter

  • H. Yoon

Principal Investigators

  • M. zgroglu

  • Y. Bang

  • M. Di Bartolomeo

  • M. Mandala

  • M. Ryu

  • L. Fornaro

  • T. Olesinski

  • C. Caglevic

  • H. Chung

  • K. Muro

  • E. Van Cutsem

  • A. Elme

  • P. Thuss-Patience

  • I. Chau

  • A. Ohtsu

  • A. Wang

  • P. Bhagia

  • J. Lin

  • C. Shih

  • K. Shitara

Medical Centers

  • Mayo Clinic, Rochester, United States

  • Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT

  • Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Pediatric Rheumatology, Istanbul, Turkey

  • Seoul National University College of Medicine, Seoul, Korea

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Papa Giovanni XXIII Hospital, Bergamo, Italy

  • Asan Medical Center, University of Ulsan, Seoul, South Korea

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • Cancer Research Department, Fundacion Arturo Lopez Perez, Santiago, Chile

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Sa Pohja-Eesti Regionaalhaigla, Tallinn, Estonia

  • Charite-Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • National Cancer Center, EPOC, Chiba, Japan

  • Merck & Co., Inc., Kenilworth, NJ, United States,

Locations

  • United States

  • Turkey

  • Republic of South Korea

  • Italy

  • Poland

  • Chile

  • Japan

  • Belgium

  • Estonia

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pembrolizumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved